The phase 3 MITO23 trial investigated trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients Dr Domenica Lorusso (Fondazione IRCCS National Cancer institute of Milan, Milan, Italy) discusses the rationale for the trial, trabectedin’s mode of action, the phase 3 results, and future planned studies.
The abstract entitled ‘Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)‘ (Abstract #LBA5504) was presented at the ASCO annual meeting, 3-7 June 2022.
Disclosures: Domenica Lorusso discloses consultancy honoraria from AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen and PharmaMar. She has has been an invited member of advisory boards at Merck Serono, Seagen, Immunogen, Genmab, Oncoinvest, Corcept and Sutro, and an invited speaker and member of the advisory board for AstraZeneca. She receives direct research institutional funding from Clovis Oncology, GSK, MSD and PharmaMar, and grants for traveling from Roche, PharmaMar, AstraZeneca, Clovis Oncology and GSK.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
